ENO1 and cardiac hypertrophy: Interestingly, in an experimental murine model of type 2 diabetes mellitus, inhibition of ENO-1 by the ENOblock reduced blood glucose concentration and LDL cholesterol levels as well as decreased secondary diabetic complications such as adipocyte size, cardiac hypertrophy, expression of inflammatory mediators and attenuated liver fibrosis (Jung et al., 2013; Cho et al., 2017).